

Lin Chang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/861331/lin-chang-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

193
papers

10,645
citations

58
h-index

100
g-index

240
ext. papers

12,541
ext. citations

5.2
avg, IF

6.28
L-index

#	Paper	IF	Citations
193	Obesity is associated with a distinct brain-gut microbiome signature that connects Prevotella and Bacteroides to the brain's reward center.. <i>Gut Microbes</i> , 2022 , 14, 2051999	8.8	1
192	Reply to Letter to Editor.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	
191	The visceral sensitivity index: A novel tool for measuring GI-symptom-specific anxiety in inflammatory bowel disease.. <i>Neurogastroenterology and Motility</i> , 2022 , e14384	4	0
190	Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis. <i>American Journal of Gastroenterology</i> , 2021 , 116, 748-757	0.7	7
189	Increasing Rates of Opioid Prescriptions for Gastrointestinal Diseases in the United States. <i>American Journal of Gastroenterology</i> , 2021 , 116, 796-807	0.7	5
188	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. <i>Nature Genetics</i> , 2021 , 53, 1543-1552	36.3	11
187	Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1576-1584	4.5	2
186	The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2541-2550.e1	6.9	7
185	Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1601-1611	0.7	5
184	Effect of Exclusion Diets on Symptom Severity and the Gut Microbiota in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	5
183	A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 281-291	6.1	0
182	The Colonic Mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p Are Downregulated in Irritable Bowel Syndrome and Are Associated With Barrier Function and MAPK Signaling. <i>Gastroenterology</i> , 2021 , 160, 2409-2422.e19	13.3	7
181	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	
180	Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1929-1937	9.7	3
179	Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 1836-1844	4	4
178	Cytokine Levels and Symptoms Among Women with Irritable Bowel Syndrome: Considering the Role of Hormonal Contraceptive Use. <i>Biological Research for Nursing</i> , 2021 , 23, 171-179	2.6	1
177	Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 4140-4148	4	2

176	A Review of the Evidence and Recommendations on Communication Skills and the Patient-Provider Relationship: AIROME Foundation Working Team Report. <i>Gastroenterology</i> , 2021 , 161, 1670-1688.e7	13.3	6
175	Latest Insights on the Pathogenesis of Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2021 , 50, 505-522	4.4	3
174	Small intestinal immunopathology and GI-associated antibody formation in hereditary alpha-tryptasemia. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 148, 813-821.e7	11.5	4
173	How to Approach a Patient with Difficult-to-Treat IBS. <i>Gastroenterology</i> , 2021 , 161, 1092-1098.e3	13.3	1
172	Postmenopausal women with irritable bowel syndrome (IBS) have more severe symptoms than premenopausal women with IBS. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13913	4	6
171	Importance of trauma-related fear in patients with irritable bowel syndrome and early adverse life events. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13896	4	4
170	Opioid Prescription Patterns Among US Gastroenterologists From 2013 to 2017. <i>Gastroenterology</i> , 2020 , 158, 776-779.e2	13.3	4
169	Risk and Protective Factors Related to Early Adverse Life Events in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2020 , 54, 63-69	3	13
168	Analysis of brain networks and fecal metabolites reveals brain-gut alterations in premenopausal females with irritable bowel syndrome. <i>Translational Psychiatry</i> , 2020 , 10, 367	8.6	7
167	Epigenetic Mechanisms in Irritable Bowel Syndrome. <i>Frontiers in Psychiatry</i> , 2020 , 11, 805	5	10
166	Negative Events During Adulthood Are Associated With Symptom Severity and Altered Stress Response in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2245-2252	6.9	11
165	Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819841290	12.9	9
164	μ-opioid receptor, κ-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2019 , 31, e13688	4	15
163	miR-24 Is Elevated in Ulcerative Colitis Patients and Regulates Intestinal Epithelial Barrier Function. <i>American Journal of Pathology</i> , 2019 , 189, 1763-1774	5.8	18
162	Activation of pruritogenic TGR5, MrgprA3, and MrgprC11 on colon-innervating afferents induces visceral hypersensitivity. <i>JCI Insight</i> , 2019 , 4,	9.9	33
161	Plasma Corticotropin-Releasing Factor Receptors and B7-2+ Extracellular Vesicles in Blood Correlate with Irritable Bowel Syndrome Disease Severity. <i>Cells</i> , 2019 , 8,	7.9	8
160	487 Use of Central Neuromodulators by Gastroenterologists in the Treatment of IBS: A Pilot Survey. <i>American Journal of Gastroenterology</i> , 2019 , 114, S282-S282	0.7	
159	489 Opioid and Neuromodulator Prescription Patterns Among U.S. Gastroenterologists. <i>American Journal of Gastroenterology</i> , 2019 , 114, S283-S283	0.7	

158	The Gut Microbiome and Digestive Health - A New Frontier. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 215-217	6.9	2
157	Predictors of Health-related Quality of Life in Irritable Bowel Syndrome Patients Compared With Healthy Individuals. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, e142-e149	3	15
156	Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1673-1676	6.9	37
155	Functional Bowel Disorders. <i>Gastroenterology</i> , 2018 , 155, 1-4	13.3	6
154	Functional Bowel Disorders: A Roadmap to Guide the Next Generation of Research. <i>Gastroenterology</i> , 2018 , 154, 723-735	13.3	33
153	Using the Rome IV Criteria to Help Manage the Complex IBS Patient. <i>American Journal of Gastroenterology</i> , 2018 , 113, 453-456	0.7	6
152	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2018 , 155, 168-179	13.3	31
151	Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. <i>Gut</i> , 2018 , 67, 263-270	19.2	79
150	Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13155	4	24
149	Sigmoid colon mucosal gene expression supports alterations of neuronal signaling in irritable bowel syndrome with constipation. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 315, G140-G157	5.1	10
148	1090 - Epigenetic Changes in Blood Cells and Colonic Mucosa are Associated with Irritable Bowel Syndrome (IBS). <i>Gastroenterology</i> , 2018 , 154, S-214	13.3	4
147	Irritable bowel syndrome patients have SCN5A channelopathies that lead to decreased Na ^{1.5} current and mechanosensitivity. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 314, G494-G503 ^{5.1}	5.1	27
146	Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2017 , 112, 892-899	0.7	28
145	Early adverse life events are associated with altered brain network architecture in a sex- dependent manner. <i>Neurobiology of Stress</i> , 2017 , 7, 16-26	7.6	33
144	Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 1186-1192	4	27
143	Sex-Related Differences in GI Disorders. <i>Handbook of Experimental Pharmacology</i> , 2017 , 239, 177-192	3.2	12
142	Gene expression profiles in peripheral blood mononuclear cells correlate with salience network activity in chronic visceral pain: A pilot study. <i>Neurogastroenterology and Motility</i> , 2017 , 29, e13027	4	16
141	Increased Sleep Disturbances in Irritable Bowel Syndrome (IBS) Patients is Associated with Greater Symptom Severity and Decreased Quality Of Life. <i>Gastroenterology</i> , 2017 , 152, S716	13.3	2

140	Dysregulation of the Long-Noncoding RNA, Ghrlos, in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017 , 152, S722	13.3	3
139	Morphological brain measures of cortico-limbic inhibition related to resilience. <i>Journal of Neuroscience Research</i> , 2017 , 95, 1760-1775	4.4	29
138	Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population. <i>Neurogastroenterology and Motility</i> , 2017 , 29, e13003	4	13
137	Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. <i>Therapeutic Advances in Gastroenterology</i> , 2017 , 10, 689-699	4.7	8
136	Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. <i>BMJ Open Gastroenterology</i> , 2017 , 4, e000134	3.9	46
135	Chronic constipation. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17095	51.1	106
134	Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. <i>Therapeutic Advances in Gastroenterology</i> , 2017 , 10, 253-275	4.7	31
133	Interactions of early adversity with stress-related gene polymorphisms impact regional brain structure in females. <i>Brain Structure and Function</i> , 2016 , 221, 1667-79	4	21
132	Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity. <i>Neurogastroenterology and Motility</i> , 2016 , 28, 1252-60	4	58
131	366 Guanylate Cyclase-C Expression Is Down-Regulated in Colonic Biopsies From Female Irritable Bowel Syndrome Patients With Constipation. <i>Gastroenterology</i> , 2016 , 150, S81-S82	13.3	2
130	Expression of the Bitter Taste Receptor, T2R38, in Enteroendocrine Cells of the Colonic Mucosa of Overweight/Obese vs. Lean Subjects. <i>PLoS ONE</i> , 2016 , 11, e0147468	3.7	38
129	Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2016 , 28, 410-22	4	24
128	2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, e77-86	6.9	3
127	Mo1616 Resilience Is Decreased in Irritable Bowel Syndrome (IBS) and Associated With Poorer Quality of Life and Greater Symptom Severity. <i>Gastroenterology</i> , 2016 , 150, S731	13.3	4
126	The effect of sex and irritable bowel syndrome on HPA axis response and peripheral glucocorticoid receptor expression. <i>Psychoneuroendocrinology</i> , 2016 , 69, 67-76	5	37
125	Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. <i>Gastroenterology</i> , 2016 ,	13.3	242
124	Bowel Disorders. <i>Gastroenterology</i> , 2016 ,	13.3	1260
123	2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016 , 2, 394-399.e2	7.9	4

122	Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 1114-1122	6.1	22
121	Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response. <i>Psychoneuroendocrinology</i> , 2016 , 73, 133-141	5	7
120	313 Effects of Rifaximin on Urgency, Bloating, and Abdominal Pain in Patients With IBS-D: A Randomized, Controlled, Repeat Treatment Study. <i>Gastroenterology</i> , 2015 , 148, S-69	13.3	7
119	Computer versus physician identification of gastrointestinal alarm features. <i>International Journal of Medical Informatics</i> , 2015 , 84, 1111-7	5.3	14
118	Diminished expression of CRHR2 in human colon cancer promotes tumor growth and EMT via persistent IL-6/Stat3 signaling. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015 , 1, 610-630	7.9	26
117	Computer-generated vs. physician-documented history of present illness (HPI): results of a blinded comparison. <i>American Journal of Gastroenterology</i> , 2015 , 110, 170-9	0.7	25
116	A cross-cultural investigation of attachment style, catastrophizing, negative pain beliefs, and symptom severity in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2015 , 27, 490-500	4	10
115	Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. <i>American Journal of Gastroenterology</i> , 2015 , 110, S761	0.7	2
114	MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. <i>Gastroenterology</i> , 2015 , 149, 981-92.e11	13.3	90
113	Catecholaminergic Gene Polymorphisms Are Associated with GI Symptoms and Morphological Brain Changes in Irritable Bowel Syndrome. <i>PLoS ONE</i> , 2015 , 10, e0135910	3.7	13
112	MicroRNA targeting for the therapy of colitis-associated colon cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 571-571	2.2	
111	American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. <i>Gastroenterology</i> , 2014 , 147, 1149-72.e2	13.3	90
110	GERD symptoms in the general population: prevalence and severity versus care-seeking patients. <i>Digestive Diseases and Sciences</i> , 2014 , 59, 2488-96	4	33
109	Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database. <i>American Journal of Gastroenterology</i> , 2014 , 109, 234-48	0.7	17
108	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1804-14	0.7	123
107	The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 1302-12	6.1	21
106	Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis. <i>Arthritis Care and Research</i> , 2014 , 66, 1725-30	4.7	19
105	Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1161-8	6.1	67

104	Guanylate Cyclase-C Receptor and Ligand Expression in Colonic Mucosa in Chronic Constipation. <i>American Journal of Gastroenterology</i> , 2014 , 109, S540	0.7	2
103	Autonomic response to a visceral stressor is dysregulated in irritable bowel syndrome and correlates with duration of disease. <i>Neurogastroenterology and Motility</i> , 2013 , 25, e650-9	4	25
102	A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. <i>Therapeutic Advances in Gastroenterology</i> , 2013 , 6, 344-57	4.7	39
101	Identification of a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1766-74	0.7	23
100	An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 1-24	0.7	1
99	Association between early adverse life events and irritable bowel syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 385-90.e1-3	6.9	194
98	Serum and colonic mucosal immune markers in irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2012 , 107, 262-72	0.7	104
97	Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. <i>American Journal of Gastroenterology</i> , 2012 , 107, 451-9	0.7	63
96	Response to Drs Trivedi and Ward. <i>American Journal of Gastroenterology</i> , 2012 , 107, 140-141	0.7	2
95	Do Patients Understand the Bristol Stool Scale? Results of Cognitive De-Briefing of IBS Patients. <i>Gastroenterology</i> , 2011 , 140, S-615	13.3	2
94	Emerging pharmacological therapies for the irritable bowel syndrome. <i>Gastroenterology Clinics of North America</i> , 2011 , 40, 223-43	4.4	14
93	The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. <i>Gastroenterology</i> , 2011 , 140, 761-5	13.3	144
92	Treatment of bloating and distension [role of probiotics: authors]reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 581-583	6.1	
91	Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1299-307	0.7	22
90	Understanding gastrointestinal distress: a framework for clinical practice. <i>American Journal of Gastroenterology</i> , 2011 , 106, 380-5	0.7	27
89	A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1803-12	0.7	131
88	Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. <i>Therapeutic Advances in Gastroenterology</i> , 2010 , 3, 291-305	4.7	10
87	Diagnosis and management of IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010 , 7, 565-81	24.2	77

86	Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. <i>American Journal of Gastroenterology</i> , 2010 , 105, 848-58	0.7	112
85	Differences in gastrointestinal symptoms according to gender in Rome II positive IBS and dyspepsia in a Latin American population. <i>American Journal of Gastroenterology</i> , 2010 , 105, 925-32	0.7	31
84	Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. <i>American Journal of Gastroenterology</i> , 2010 , 105, 866-75	0.7	70
83	Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID. <i>American Journal of Gastroenterology</i> , 2010 , 105, 722-30	0.7	18
82	An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 1-12	0.7	6
81	Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1984-91	0.7	49
80	A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. <i>Digestive Diseases and Sciences</i> , 2009 , 54, 1532-41	4	83
79	Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. <i>Gastroenterology</i> , 2009 , 137, 1954-62	13.3	147
78	Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome?. <i>Gender Medicine</i> , 2009 , 6 Suppl 2, 152-67		91
77	Do Proton Pump Inhibitors (PPIs) Predispose to the Development of SIBO in IBS versus Non-IBS Patients?. <i>American Journal of Gastroenterology</i> , 2009 , 104, S103-S104	0.7	2
76	Is IBS a Predictor of SIBO as Identified by Hydrogen/Methane Breath Testing?. <i>American Journal of Gastroenterology</i> , 2009 , 104, S110	0.7	1
75	Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. <i>Gastroenterology</i> , 2008 , 135, 1877-91	13.3	57
74	T1026 Measuring IBS Patient Reported Outcomes with a Single Item Numeric Rating Scale: Results from the PROOF Cohort. <i>Gastroenterology</i> , 2008 , 134, A-467	13.3	3
73	Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2972-6	0.7	77
72	Predictors of patient-assessed illness severity in irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2536-43	0.7	94
71	Functional GI disorders: from animal models to drug development. <i>Gut</i> , 2008 , 57, 384-404	19.2	121
70	New treatments for irritable bowel syndrome in women. <i>Women's Health</i> , 2008 , 4, 605-22; quiz 623	3	14
69	Increased acoustic startle responses in IBS patients during abdominal and nonabdominal threat. <i>Psychosomatic Medicine</i> , 2008 , 70, 920-7	3.7	35

68	Novel techniques to study visceral hypersensitivity in irritable bowel syndrome. <i>Current Gastroenterology Reports</i> , 2008 , 10, 369-78	5	12
67	Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. <i>Gastroenterology Clinics of North America</i> , 2007 , 36, 665-85, x	4.4	39
66	Attentional modulation of visceral and somatic pain. <i>Neurogastroenterology and Motility</i> , 2007 , 19, 569-77		56
65	Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome. <i>Women's Health</i> , 2007 , 3, 15-27	3	4
64	The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. <i>Psychosomatic Medicine</i> , 2007 , 69, 89-98	3.7	163
63	Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006 , 291, R277-84	3.2	77
62	Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1069-79	0.7	127
61	Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. <i>Gastroenterology</i> , 2006 , 130, 1435-46	13.3	263
60	Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. <i>Gastroenterology</i> , 2006 , 131, 352-65	13.3	155
59	Irritable bowel syndrome: new and emerging therapies. <i>Current Opinion in Internal Medicine</i> , 2006 , 22, 128-35		3
58	Brain responses to visceral and somatic stimuli in irritable bowel syndrome: a central nervous system disorder?. <i>Gastroenterology Clinics of North America</i> , 2005 , 34, 271-9	4.4	49
57	Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2005 , 100, 896-904	0.7	92
56	Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. <i>Pain</i> , 2005 , 115, 398-409	8	219
55	Cortical processing of visceral and somatic stimulation: differentiating pain intensity from unpleasantness. <i>Neuroscience</i> , 2005 , 133, 533-42	3.9	110
54	Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome?. <i>Gastrointestinal Endoscopy</i> , 2005 , 62, 892-9	5.2	61
53	A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. <i>American Journal of Gastroenterology</i> , 2005 , 100, 115-23	0.7	100
52	Impact of irritable bowel syndrome on patients' lives: development and psychometric documentation of a disease-specific measure for use in clinical trials. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 411-20	2.2	47
51	Diagnosis and treatment of irritable bowel syndrome: state of the art. <i>Current Gastroenterology Reports</i> , 2005 , 7, 249-56	5	27

50	New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments. <i>Current Gastroenterology Reports</i> , 2005 , 7, 272-9	5	38
49	A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. <i>Gut</i> , 2005 , 54, 1707-13	19.2	119
48	Sex specific alterations in autonomic function among patients with irritable bowel syndrome. <i>Gut</i> , 2005 , 54, 1396-401	19.2	108
47	A comparison of visceral and somatic pain processing in the human brainstem using functional magnetic resonance imaging. <i>Journal of Neuroscience</i> , 2005 , 25, 7333-41	6.6	203
46	Review article: epidemiology and quality of life in functional gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20 Suppl 7, 31-9	6.1	234
45	Sex-based differences in gastrointestinal pain. <i>European Journal of Pain</i> , 2004 , 8, 451-63	3.7	78
44	Racial differences in the impact of irritable bowel syndrome on health-related quality of life. <i>Journal of Clinical Gastroenterology</i> , 2004 , 38, 782-9	3	31
43	The effect of life stress on symptoms of heartburn. <i>Psychosomatic Medicine</i> , 2004 , 66, 426-34	3.7	111
42	Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. <i>Archives of Internal Medicine</i> , 2004 , 164, 1773-80		131
41	Gender-Related Differences in Functional Bowel Disorders 2004 , 438-445		1
40	Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1354-61	0.7	89
39	Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. <i>American Journal of Gastroenterology</i> , 2003 , 98, 135-43	0.7	166
38	Clinical determinants of health-related quality of life in irritable bowel syndrome. <i>Gastroenterology</i> , 2003 , 124, A398	13.3	2
37	Sex-related differences in IBS patients: central processing of visceral stimuli. <i>Gastroenterology</i> , 2003 , 124, 1738-47	13.3	238
36	Impact of sex and gender on irritable bowel syndrome. <i>Biological Research for Nursing</i> , 2003 , 5, 56-65	2.6	69
35	Prevalence of irritable bowel syndrome among university students: the roles of worry, neuroticism, anxiety sensitivity and visceral anxiety. <i>Journal of Psychosomatic Research</i> , 2003 , 55, 501-5	4.1	116
34	Irritable Bowel Syndrome. <i>Current Treatment Options in Gastroenterology</i> , 2002 , 5, 267-278	2.5	7
33	Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. <i>American Journal of Gastroenterology</i> , 2002 , 97, 2803-11	0.7	74

32	Is there a difference between abdominal pain and discomfort in moderate to severe IBS patients?. <i>American Journal of Gastroenterology</i> , 2002 , 97, 3131-8	0.7	21
31	Enhanced preattentive central nervous system reactivity in irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2002 , 97, 2791-7	0.7	50
30	Condition-specific deactivation of brain regions by 5-HT ₃ receptor antagonist Alosetron. <i>Gastroenterology</i> , 2002 , 123, 969-77	13.3	119
29	Gender differences in irritable bowel syndrome. <i>Gastroenterology</i> , 2002 , 123, 1686-701	13.3	233
28	Evolving pathophysiological model of functional gastrointestinal disorders: implications for treatment. <i>The European Journal of Surgery Supplement: = Acta Chirurgica Supplement</i> , 2002 , 3-9		7
27	Gender-related differences in IBS symptoms. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2184-93	0.7	172
26	Basic pathophysiologic mechanisms in irritable bowel syndrome. <i>Digestive Diseases</i> , 2001 , 19, 212-8	3.2	65
25	The effect of the 5-HT ₃ receptor antagonist alosetron on regional brain activation in IBS patients is not dependent on activation of nociceptive visceral afferents: A H ₂ 15O PET study. <i>Gastroenterology</i> , 2001 , 120, A67	13.3	2
24	Comment on Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. Chang et al., PAIN 84 (2000) 297-307. <i>Pain</i> , 2001 , 91, 404-405	8	
23	The role of gender and bowel habit predominance on visceral perception in IBS. <i>Gastroenterology</i> , 2001 , 120, A755	13.3	3
22	Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2001 , 96, 3341-7	0.7	139
21	V. Stress and irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2001 , 280, G519-24	5.1	306
20	Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. <i>Psychosomatic Medicine</i> , 2001 , 63, 365-75	3.7	254
19	Preoperative versus postoperative endoscopic retrograde cholangiopancreatography in mild to moderate gallstone pancreatitis: a prospective randomized trial. <i>Annals of Surgery</i> , 2000 , 231, 82-7	7.8	99
18	Gender differences in regional brain response to visceral pressure in IBS patients. <i>European Journal of Pain</i> , 2000 , 4, 157-72	3.7	142
17	Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. <i>American Journal of Gastroenterology</i> , 2000 , 95, 152-6	0.7	66
16	Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. <i>Pain</i> , 2000 , 84, 297-307	8	144
15	Towards an integrative model of irritable bowel syndrome. <i>Progress in Brain Research</i> , 2000 , 122, 413-232.		20

14	A double blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. <i>Gastroenterology</i> , 2000 , 118, A846	13.3	20
13	Differences in rectal mechanoelastic properties according to predominant bowel habit in IBS patients. <i>Gastroenterology</i> , 2000 , 118, A667	13.3	2
12	Evidence for selective effect of the 5HT3 antagonist alosetron on amygdala and hippocampal activation in IBS patients. <i>Gastroenterology</i> , 2000 , 118, A81	13.3	2
11	Evidence for decreased activation of central fear circuits by expected aversive visceral stimuli in IBS patients. <i>Gastroenterology</i> , 2000 , 118, A137	13.3	6
10	Approaches to the Modulation of Abdominal Pain. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1999 , 13, 66A-70A		5
9	Symptom differences in moderate to severe IBS patients based on predominant bowel habit. <i>American Journal of Gastroenterology</i> , 1999 , 94, 2929-35	0.7	91
8	Diagnostic approach to the patient with irritable bowel syndrome. <i>American Journal of Medicine</i> , 1999 , 107, 20S-26S	2.4	24
7	Brain-gut interactions: implications for newer therapy. <i>The European Journal of Surgery</i> , 1998 , 50-5		4
6	The association of functional gastrointestinal disorders and fibromyalgia. <i>The European Journal of Surgery</i> , 1998 , 32-6		35
5	Gallstone pancreatitis: a prospective study on the incidence of cholangitis and clinical predictors of retained common bile duct stones. <i>American Journal of Gastroenterology</i> , 1998 , 93, 527-31	0.7	65
4	Does mind-body medicine have a role in gastroenterology?. <i>Current Opinion in Gastroenterology</i> , 1997 , 13, 1-4	3	8
3	Early computed tomography is rarely necessary in gallstone pancreatitis. <i>American Surgeon</i> , 1997 , 63, 904-7	0.8	8
2	Admission factors can predict the need for ICU monitoring in gallstone pancreatitis. <i>American Surgeon</i> , 1996 , 62, 815-9	0.8	12
1	Clostridial bacteremia: implications for the surgeon. <i>American Surgeon</i> , 1991 , 57, 388-93	0.8	9